These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29987844)

  • 21. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
    Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
    Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer.
    Carethers JM; Stoffel EM
    World J Gastroenterol; 2015 Aug; 21(31):9253-61. PubMed ID: 26309352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
    Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R
    Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expanding the genotype-phenotype spectrum in hereditary colorectal cancer by gene panel testing.
    Rohlin A; Rambech E; Kvist A; Törngren T; Eiengård F; Lundstam U; Zagoras T; Gebre-Medhin S; Borg Å; Björk J; Nilbert M; Nordling M
    Fam Cancer; 2017 Apr; 16(2):195-203. PubMed ID: 27696107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
    Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
    Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The association of low penetrance genetic risk modifiers with colorectal cancer in lynch syndrome patients: a systematic review and meta-analysis.
    Donald N; Malik S; McGuire JL; Monahan KJ
    Fam Cancer; 2018 Jan; 17(1):43-52. PubMed ID: 28508326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
    Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
    J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of chromosomal copy number variations and novel candidate loci in hereditary nonpolyposis colorectal cancer with mismatch repair proficiency.
    Chen W; Yuan L; Cai Y; Chen X; Chi Y; Wei P; Zhou X; Shi D
    Genomics; 2013 Jul; 102(1):27-34. PubMed ID: 23434627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genome-wide CNV analysis in 221 unrelated patients and targeted high-throughput sequencing reveal novel causative candidate genes for colorectal adenomatous polyposis.
    Horpaopan S; Spier I; Zink AM; Altmüller J; Holzapfel S; Laner A; Vogt S; Uhlhaas S; Heilmann S; Stienen D; Pasternack SM; Keppler K; Adam R; Kayser K; Moebus S; Draaken M; Degenhardt F; Engels H; Hofmann A; Nöthen MM; Steinke V; Perez-Bouza A; Herms S; Holinski-Feder E; Fröhlich H; Thiele H; Hoffmann P; Aretz S
    Int J Cancer; 2015 Mar; 136(6):E578-89. PubMed ID: 25219767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequency of rearrangements in Lynch syndrome cases associated with MSH2: characterization of a new deletion involving both EPCAM and the 5' part of MSH2.
    Pérez-Cabornero L; Infante Sanz M; Velasco Sampedro E; Lastra Aras E; Acedo Becares A; Miner Pino C; Durán Domínguez M
    Cancer Prev Res (Phila); 2011 Oct; 4(10):1556-62. PubMed ID: 21791569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mismatch repair genes founder mutations and cancer susceptibility in Lynch syndrome.
    Ponti G; Castellsagué E; Ruini C; Percesepe A; Tomasi A
    Clin Genet; 2015 Jun; 87(6):507-16. PubMed ID: 25345868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of novel, large duplications in the MSH2 gene of three unrelated Lynch syndrome patients.
    Liccardo R; De Rosa M; Rossi GB; Rigler G; Izzo P; Duraturo F
    Cancer Genet; 2018 Feb; 221():19-24. PubMed ID: 29405992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of MSH2 and MSH6 due to heterozygous germline defects in MSH3 and MSH6.
    Morak M; Käsbauer S; Kerscher M; Laner A; Nissen AM; Benet-Pagès A; Schackert HK; Keller G; Massdorf T; Holinski-Feder E
    Fam Cancer; 2017 Oct; 16(4):491-500. PubMed ID: 28528517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional analysis of MSH2 unclassified variants found in suspected Lynch syndrome patients reveals pathogenicity due to attenuated mismatch repair.
    Wielders EA; Hettinger J; Dekker R; Kets CM; Ligtenberg MJ; Mensenkamp AR; van den Ouweland AM; Prins J; Wagner A; Dinjens WN; Dubbink HJ; van Hest LP; Menko F; Hogervorst F; Verhoef S; te Riele H
    J Med Genet; 2014 Apr; 51(4):245-53. PubMed ID: 24501230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of colonic and endometrial carcinomas in Portuguese families with hereditary nonpolyposis colorectal carcinoma significantly increases the probability of detecting a pathogenic mutation in mismatch repair genes, primarily the MSH2 gene.
    Lage PA; Albuquerque C; Sousa RG; Cravo ML; Salazar M; Francisco I; Maia L; Claro I; Suspiro A; Rodrigues P; Raposo H; Fidalgo PA; Nobre-Leitão C
    Cancer; 2004 Jul; 101(1):172-7. PubMed ID: 15222003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
    Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
    Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined mismatch repair and POLE/POLD1 defects explain unresolved suspected Lynch syndrome cancers.
    Jansen AM; van Wezel T; van den Akker BE; Ventayol Garcia M; Ruano D; Tops CM; Wagner A; Letteboer TG; Gómez-García EB; Devilee P; Wijnen JT; Hes FJ; Morreau H
    Eur J Hum Genet; 2016 Jul; 24(7):1089-92. PubMed ID: 26648449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Large genomic rearrangements and germline epimutations in Lynch syndrome.
    Gylling A; Ridanpää M; Vierimaa O; Aittomäki K; Avela K; Kääriäinen H; Laivuori H; Pöyhönen M; Sallinen SL; Wallgren-Pettersson C; Järvinen HJ; Mecklin JP; Peltomäki P
    Int J Cancer; 2009 May; 124(10):2333-40. PubMed ID: 19173287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical characterization and mutation spectrum in Caribbean Hispanic families with Lynch syndrome.
    Cruz-Correa M; Diaz-Algorri Y; Pérez-Mayoral J; Suleiman-Suleiman W; Gonzalez-Pons Mdel M; Bertrán C; Casellas N; Rodríguez N; Pardo S; Rivera K; Mosquera R; Rodriguez-Quilichini S
    Fam Cancer; 2015 Sep; 14(3):415-25. PubMed ID: 25782445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hereditary non-polyposis colorectal cancer/Lynch syndrome in three dimensions.
    Kravochuck SE; Church JM
    ANZ J Surg; 2017 Dec; 87(12):1006-1010. PubMed ID: 26990828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.